Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Clinical trial NCT01742286 · COMPLETED
Trial details
- NCT number
- NCT01742286
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-28
- Primary completion
- 2019-04-26
- Enrollment
- 83
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.